CA
NZ
UK
AU
IND
US
The screener showsReturn on Equityof 29.49%, gross margin of 70.11%, anOperating Marginof negative 0.40% and net margin of 24.23%. The net margin ties to published trailing figures, with net income of USD 111.01 million on revenue of USD 458.09 million, up 34.4%. The July …
The screener tagged news, but no filing or release dated October 7 or 8, 2026 was found. The stock gapped up 8.88%, then traded 2.12% below its open, andVolumeof 7.1 million shares against about 3.06 million shares outstanding points to heavy short-term trading. The …
The screener flagged analyst action, but the nearest items found were a Barclays Sell initiation with a USD 8 target on October 6 and a Wells Fargo Hold with a USD 15 target on October 2, both from an aggregator and neither dated October …
The screener showed no catalyst, and none was found for October 7 or 8, 2026. The stock gapped up 0.59% and then climbed 5.00% from the open, which means buyers were active after the bell, thoughVolumewas only 159,143 shares, or 0.2 times normal. The …
On October 8, 2026 the company said the Japan Patent Office issued a notice of allowance for a method covering its CyPath Lung test, which uses automated flow cytometry andMachine Learningto detect early-stage lung cancer in sputum. Issuance follows payment of a fee. A …
Quanterix makes Simoa, an ultrasensitive technology that detects very low levels of proteins in blood and tissue. On September 14, 2026 it hired Dr. Yuri Fesko as chief medical officer to help launch the Lucent AD Complete five-biomarker Alzheimer's test and file the HD-X …
ImmunityBio closed at USD 7.72 on September 10, 2026, then climbed to USD 9.29 on September 22 on 21.1 million shares and USD 9.44 on September 30 on 27.3 million. On October 2 it rose 10.9% to USD 10.29 on 31.3 million shares, a …
AngioDynamics delivered its eighth consecutive quarter of double-digit Med Tech growth and positive adjusted EBITDA. Yet Med Tech growth slowed from 16.7 percent in the fourth quarter to 13.2 percent, guidance was reiterated rather than lifted, and the stock had gained more than 20 …
Ginkgo has pivoted from cell programming services to automated labs and data products, including Datapoints for AI models, an ARPA-H program and partnerships with Apheris and large drug makers. Revenue is shrinking, with a USD 47 million lab deal announced alongside the second-quarter loss, …
The August results lifted the shares to a 52-week high of about USD 2.79, per published reports, and the stock has since more than doubled, so a single-day drop of 5.92 percent on very light volume is modest against the move. The analyst action …
Please wait processing your request...